Brian Stuglik (pictured above) has been named the new chief executive of Boston-based biotech Verastem Oncology (Nasdaq: VSTM).
The announcement comes around five weeks after the resignation of former CEO Robert Forrester.
"Brian brings deep commercial and biopharmaceutical leadership experience that we believe will accelerate the growth of Copiktra"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze